Tex. Health and Safety Code § 491.060: ALLOCATION OF REVENUE ATTRIBUTABLE TO INTELLECTUAL PROPERTY AND OTHER RIGHTS.
Where this section sits in the code
- HEALTH AND SAFETY CODE
- TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES
- SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES Chapter 491, consisting of Secs. 491.001 to 491.103, was added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1. For another Chapter 491, consisting of Secs. 491.001 to 491.151, added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, see Sec. 491.001 et seq., post. For another Chapter 491, consisting of Secs. 491.001 to 491.151, added by Acts 2025, 89th Leg., R.S., Ch. 352 (S.B. 670), Sec. 2, see Sec. 491.001 et seq., post.
- CHAPTER 491. IBOGAINE TREATMENT
- SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT
(a) The revenue attributable to all intellectual property rights and other commercial rights arising from drug development clinical trials conducted by a consortium under this subchapter during the period for which the trials are funded and any following period of commercialization shall be allocated as follows:
(1) not less than 20 percent to the state as specified in the contract under Section 491.055; and
(2) the remainder to the members of the consortium in the amounts specified by written agreement of the members.
(b) For purposes of this section, intellectual property rights and other commercial rights arising from the drug development clinical trials conducted under this subchapter include any of the following as related to the trials:
(1) intellectual property, technology, and inventions;
(2) patents, trademarks, and licenses;
(3) proprietary and confidential information;
(4) trade secrets, data, and databases;
(5) tools, methods, and processes;
(6) treatment models or techniques;
(7) administration protocols; and
(8) works of authorship.
Added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1, eff. June 11, 2025.
Collected 2026-08-27T01:47:17Z. Source file · JSON